InvestorsHub Logo
Followers 87
Posts 6641
Boards Moderated 1
Alias Born 09/18/2009

Re: cowtown jay post# 42287

Saturday, 04/13/2024 5:55:13 PM

Saturday, April 13, 2024 5:55:13 PM

Post# of 42746
"The new Humanigen may be stronger than I expected."

At one point, I actually questioned why the CH11 bankruptcy would be necessary. If Humanigen owns 110M of the 119M shares they have issued, and if our float of 229M shares is 192% of our OS, that could only mean that Humanigen has loaned the excess shares in our market. If so, Humanigen would be positioned to issue a recall of their loaned shares, and cause an even more massive short squeeze than they did as Kalobios.

I see no change in those circumstances.

I think Humanigen has held off recalling their loaned shares, until news, such as in regards to regulatory approval or authorization of lenzilumab, or news regarding a business combination/merger/partnership, was ready to be announced. This extended delay caused the financial constraints that forced the CH11 (as the US regulators tried to force us out of business, and protect their financial investment in Moderna, and promote their mRNA ideology, in my opinion).

I really think that Novavax may have used lenz as an enhancement in their prototype vaccine. I also think that Sanofi graduated, as Gracell did, from Humanigen's incubation of their their products, used with lenz for enhanced safety and efficacy. And I note how this CH11 is nearing completion as Sanofi prepares to spin-off their healthcare division, and the PREACH-M trial results are placed for regulatory approval in Australia, perhaps with a Priority Review Voucher worth ~$100M.

The only things that have changed are:

We may have partnership interests from Novavax, PREACH-M (and/or Sanofi), and Gracell (and perhaps AstraZeneca), exerting authorization approval of lenz from Regulators (probably overseas).

We have no secured debt obligations.

We have non-debtor Humanigen subsidiaries prepared for possible merger use in the UK, Australia, and the Republic of Ireland.

And we have shocking safety and efficacy failures, to include vaccine injuries and excess deaths, caused by the standard of care currently in use.

I'm very optimistic, and I believe that Humanigen has never been stronger than we are now.